Arrowhead Pharmaceuticals

Yahoo Finance • 28 days ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • last month

Arrowhead sues Ionis over patent dispute related to lead asset

[Patent] JLGutierrez Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) sued Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) in a Delaware District Court on Wednesday as part of a pat... Full story

Yahoo Finance • last month

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc.... Full story

Yahoo Finance • last month

Medpace Holdings, Inc. (MEDP): A Bull Case Theory

We came across a bullish thesis on Medpace Holdings, Inc.  on Rocky&Turner’s Substack by James Emanuel. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. 's share was trading at $475.51 as of August 29th.... Full story

Yahoo Finance • last month

Alphabet, Apple Stock Soars After Judge Says Chrome Sale Not Required

This article first appeared on GuruFocus. Sep 3 - Alphabet (NASDAQ:GOOGL) jumped on Wednesday, rising more than 7%, as investors reacted to a favorable antitrust ruling. A federal judge decided Google would not be forced to divest its Chr... Full story

Yahoo Finance • last month

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

- Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Park... Full story

Yahoo Finance • 2 months ago

Mizuho maintains Sarepta Therapeutics stock rating, lowers Elevidys sales forecast

Investing.com - Mizuho maintained its Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) following the company’s second-quarter 2025 earnings report and debt refinancing. The stock, currently trading at $20.22,... Full story

Yahoo Finance • 2 months ago

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investor... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

- Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment - Sarepta sells at least $174 million of Arrowhead common s... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $10... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics stock holds steady as TD Cowen reiterates $17 target

Investing.com - TD Cowen has reiterated its Hold rating and $17.00 price target on Sarepta Therapeutics (NASDAQ:SRPT), whose shares have fallen over 85% in the past year, following the company’s first Duchenne muscular dystrophy (DMD) pa... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharma stock price target lowered to $21 at Leerink Partners

Investing.com - Leerink Partners has lowered its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $21.00 from $22.00 while maintaining a Market Perform rating following the company’s fiscal third-quarter 2025 results. The stock,... Full story

Yahoo Finance • 2 months ago

Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks

[Stock market concept] Mikko Lemola The S&P500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the red on Friday after the we... Full story

Yahoo Finance • 2 months ago

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market... Full story

Yahoo Finance • 2 months ago

Bernstein initiates Sarepta Therapeutics stock with Market Perform rating

Investing.com - Bernstein SocGen Group initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Market Perform rating and a $13.00 price target on Tuesday, as the company approaches its next earnings release on July 30. The ratin... Full story

Yahoo Finance • 3 months ago

Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) Monday announced [https://seekingalpha.com/pr/20179072-arrowhead-pharmaceuticals-earns-100-million-milestone-from-sarepta-therapeutics] that it has earned a $10... Full story

Yahoo Finance • 3 months ago

Barclays downgrades Sarepta stock to Underweight on Elevidys concerns

Investing.com - Barclays downgraded Sarepta Therapeutics (NASDAQ:SRPT) from Equalweight to Underweight and slashed its price target to $10.00 from $18.00 on Monday. The stock, currently trading at $11.93, has plummeted 90% year-to-date a... Full story

Yahoo Finance • 3 months ago

Eli Lilly, GE Vernova Surge Among Wednesday's Market Cap Stock Movers

Wednesday’s market has seen significant activity, with stocks like Eli Lilly And Co (NYSE:LLY) and GE Vernova LLC (GEV) experiencing notable increases, while Fiserv Inc (NYSE:FI) (FISV) faced a sharp decline. These movements reflect a... Full story

Yahoo Finance • 3 months ago

Google, Linde lead market cap stock movers on Monday

Monday’s trading session is showcasing notable movements across various stock categories, with mega-caps like Google Inc (NASDAQ:GOOGL) and Linde AG (ETR:LING) (LIN) experiencing positive shifts, while large-cap stocks such as Astera L... Full story

Yahoo Finance • 3 months ago

Stocks making the biggest moves midday: Block, SolarEdge, Cleveland-Cliffs, Verizon & more

Check out the companies making the biggest moves midday: Bruker — The lab instrument and tools maker shed 12% after the company issued weaker-than-expected guidance for the second quarter. The company expects to earn between 32 and 34 cent... Full story